Setting new standards in information exchange for the pharmaceutical and biotech industry
Mylan & Iroko Co-Charis Discuss the Upcoming MRS Summit
February 10, 2014
As co-chairs of the 2nd Annual Medicaid Rebate Summit we wanted to share some of the anticipated highlights with you.
The organizers have built on the success from last year’s event to line up a diverse group of industry experts and a wide-ranging agenda. Highlights from this year’s program include:
- Full coverage on 340B covered entity repayments, double discounts, diversions, integrity initiatives, and audit reporting
- Federal regulations update impacting pharmaceutical pricing and contracting rules
- How to bridge commercial contracting strategy with government program rules
We are specifically looking forward to our Keynote speaker Adam Fein, who should be both enlightening and entertaining as readers of his Drug Channels blog know and Alice Valder Curran, who always has great insights on government pricing topics and it sounds as if she’s going to do a deeper dive into how to handle 340B Covered entity rules.
We hope that you’ll be able to join us.
Jim Abrams, MBA
Director Government Pricing & Reporting, Mylan Pharmaceuticals
Senior Director Managed Markets & HCP Compliance, Iroko Pharmaceuticals